Among cytokine families, in the last 15 years, the biology of receptor activator nuclear factor-κB ligand (RANKL) and its receptor RANK has been widely studied in cancer [20–23] and has been identified as a key therapeutic target in numerous cancer entities, as described below. Here, TNFRSF11A is linked to cancer.